January 4, 2017
Gilead reinforces oncology department from Novartis
Gilead Sciences has strengthened its lines with newly appointed Hematology and Oncology Therapeutic Area Head, who came from Novartis.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Alessandro Riva
October 9, 2016
Novartis: exploring Zykadia’s efficacy in ALK+ NSCLC patients grows
Novartis today announced updated results from a Phase II study (ASCEND-3), which demonstrated that anaplastic lymphoma kinase-positive (ALK+) non-small cell…
September 28, 2015
Afinitor (everolimus) tablets reduced the risk of progression of neuroendocrine tumors
Novartis has announced results of a Phase III pivotal study showing Afinitor (everolimus) tablets reduced the risk of progression by 52% vs placebo in patients with advanced, progressive, nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin.